Open-label, Non-randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Lymphoma
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs PQR 309 (Primary)
- Indications Lymphoid leukaemia; Lymphoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 15 Jul 2017 Planned number of patients changed from 72 to 100.
- 20 Mar 2017 Status changed from suspended to recruiting.
- 03 Dec 2016 Status changed from recruiting to suspended.